The US Food and Drug Administration recently approved ivabradine to treat chronic heart failure caused by improper contracting of the left-ventricle and to reduce hospitalization.
The FDA approved the Impella 2.5 System to help stabilize circulation and heart function during high-risk percutaneous coronary intervention procedures.